Stay updated on Argonaut Clinical Trial: BBP-398 & Sotorasib in KRAS-G12C
Sign up to get notified when there's something new on the Argonaut Clinical Trial: BBP-398 & Sotorasib in KRAS-G12C page.

Latest updates to the Argonaut Clinical Trial: BBP-398 & Sotorasib in KRAS-G12C page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase 1 study of the SHP2 inhibitor BBP-398 and its combination with sotorasib, while adding references to NAV-1003 and a new revision number.SummaryDifference16%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Argonaut Clinical Trial: BBP-398 & Sotorasib in KRAS-G12C
Enter your email address, and we'll notify you when there's something new on the Argonaut Clinical Trial: BBP-398 & Sotorasib in KRAS-G12C page.